BRISBANE, Calif., April 21, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces the appointment of Michael Bell as Chief Financial Officer joining CareDx effective April 21, 2017, and succeeding Charles Constanti. The board and the company thank Mr. Constanti for his valuable contributions and financial expertise during their acquisition year. Mr. Constanti will remain with the company until June 30th to facilitate a smooth transition.
“CareDx is gearing up for the launch of AlloSure, its next-generation post-transplant rejection testing service, while at the same time driving its existing transplantation product lines, AlloMap and Olerup, towards profitability,” said Peter Maag, CareDx president and chief executive officer. “Michael’s broad experience in finance and operations, coupled with his knowledge of the diagnostics industry, will guide our efforts to provide novel diagnostic solutions to transplantation physicians and patients, while delivering value to our shareholders.”
Michael Bell brings over 20 years of international finance and accounting experience. Michael is the former CFO of Metabiota, an infectious disease risk analytics company. Previously, he served as the CFO of Singulex, a clinical diagnostics company, and has held leadership and executive positions within Novartis, including tenure as the CFO of Novartis Diagnostics, a global provider of blood screening solutions. Previously, Michael worked in public accounting at Ernst & Young and Deloitte. Michael holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection. CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing-based test to detect donor-derived cell-free DNA after transplantation.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium.
For more information, please visit: www.CareDx.com.
Contact Sasha King, Head of Marketing T: +1 415-287-2393 E: sking@caredx.com
